High Vista Strategies LLC Iovance Biotherapeutics, Inc. Transaction History

High Vista Strategies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$5.36 - $9.06 $356,579 - $602,725	66,526 New	66,526 $468,000
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $258,663 - $355,831	27,142 Added 60.37%	72,104 $691,000
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $60,220 - $173,016	-9,439 Reduced 17.35%	44,962 $496,000
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $151,506 - $233,745	-12,238 Reduced 18.36%	54,401 $906,000
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $171,507 - $286,329	10,363 Added 18.41%	66,639 $1.27 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $484,696 - $634,273	23,818 Added 73.38%	56,276 $1.39 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $233,437 - $472,735	14,295 Added 78.7%	32,458 $845,000
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $64,794 - $118,853	-2,260 Reduced 11.07%	18,163 $575,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $100,915 - $180,885	3,599 Added 21.39%	20,423 $948,000
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $37,268 - $48,750	1,343 Added 8.68%	16,824 $554,000
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $421,238 - $634,721	15,481 New	15,481 $425,000

313

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.